• Pigmentation of the iris (likely to be permanent), periorbital tissue (eyelid) and eyelashes can occur; and
  • Eyelash changes such as gradual change to eyelashes including increased length, thickness and number of lashes, which is usually reversible upon discotinuation of treatment.

 
XELPROSTM will be commercialized in the U.S. by Sun Ophthalmics.